INSM

Rating neutralAI MemoPost-earnings T+3

Insmed

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and raised BRINSUPRI guidance • 2026-08-06

Base target: $140 / p=45% prob

Biggest risk

The stock already reflects substantial commercial and pipeline expectations. Any slowdown in BRINSUPRI uptake, regulatory delay, weaker TPIP evidence, or higher launch and development spending could compress the premium. Post-print analyst revisions are not available in the packet.

Invalidation

Break below $100 or thesis failure.

What would change my mind?

Q2 results support a strong BRINSUPRI launch, the raised revenue guide improves near-term visibility, and ARIKAYCE label expansion plus TPIP Phase 3 programs provide additional upside optionality [#SEC-8K-2026-08-06].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$140

p=45%

Bull target

$190

p=30%

Bear target

$100

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BRINSUPRI launch execution
ARIKAYCE label-expansion pathway
TPIP Phase 3 progression

BearKey bullets

ARIKAYCE label expansion and the brensocatib Japan decision remain pending, while evolving U.S.
policies may affect international launch timing [#SEC-8K-2026-08-06].
BRINSUPRI launch momentum may decelerate or fail to support the raised $1.25-$1.40 billion 2026 guidance.

WatchKey bullets

Q2 2026 results and raised BRINSUPRI guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $140 (p=45%)

Target spread vs base: +36% / -29%

Scenario probabilities

Bull Target: $190 (p=30%)Base Target: $140 (p=45%)Bear Target: $100 (p=25%)

Commentary

News tone is positive following the reported revenue growth and raised BRINSUPRI guidance, but social, options, short-interest, and employee-sentiment data are unavailable. The available post-print price snapshot remained near the $132.55 anchor, suggesting no confirmed durable repricing yet. Analyst target or estimate revisions after the print are unavailable, so the evidence supports monitoring rather than high-conviction directional positioning.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BRINSUPRI launch execution
ARIKAYCE label-expansion pathway
TPIP Phase 3 progression

Scenarios

Bull Target (Scenario probability)

$190 / p=30% prob

Base Target (Scenario probability)

$140 / p=45% prob

Bear Target (Scenario probability)

$100 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 results and raised BRINSUPRI guidance
Insmed reported Q2 revenue of $425.5 million, including BRINSUPRI revenue of $309.2 million, up 49% sequentially, and raised 2026 BRINSUPRI guidance to $1.25-$1.40 billion while reiterating ARIKAYCE guidance of $450-$470 million [#SEC-8K-2026-08-06]. A pre-release Zacks reference cited $389.72 million revenue; primary-source EPS comparison is unavailable [#PR-EARNINGS-2026-07-30].
Prob 95.00% • Move 8.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

BRINSUPRI launch execution
2026-09-30
The immediate operating test is whether the 49% sequential BRINSUPRI growth rate and strong U.S. demand can support the raised 2026 revenue range without meaningful access, payer, or launch-friction deterioration [#SEC-8K-2026-08-06].
Prob 65% • Move 7% • Priced-in 60%

Long-term Catalysts

Months to a year

ARIKAYCE label-expansion pathway
2027-08-08
Insmed plans an FDA supplemental application for ARIKAYCE in the second half of 2026 after positive Phase 3b ENCORE results, with parallel Japanese review potential [#SEC-8K-2026-05-07]. Submission progress and regulatory outcomes remain uncertain.
Prob 65% • Move 14% • Priced-in 45%
TPIP Phase 3 progression
2027-08-08
Management is advancing TPIP Phase 3 programs across four indications. Prior open-label extension data showed sustained improvement, but the non-placebo-controlled design limits confidence until controlled Phase 3 evidence arrives [#8-K-2026-07-16].
Prob 55% • Move 18% • Priced-in 50%

Risks

ARIKAYCE label expansion and the brensocatib Japan decision remain pending, while evolving U.S. policies may affect international launch timing [#SEC-8K-2026-08-06].
BRINSUPRI launch momentum may decelerate or fail to support the raised $1.25-$1.40 billion 2026 guidance.
High expectations around more than $14 billion of combined peak sales increase downside sensitivity to execution or regulatory disappointment [#SEC-8K-2026-08-06].
Recent Form 4 filings show open-market sales by the chief medical officer; this is sentiment context rather than evidence about operating performance [#SEC-FORM4-2026-08-07].
TPIP evidence remains early and includes open-label, non-placebo-controlled data; Phase 3 efficacy and safety outcomes are unproven [#8-K-2026-07-16].

Peers

Symbol	Summary
ALNY	Similar-size biopharma benchmark with commercial and pipeline exposure, but different modalities and disease focus make it an indirect comp.
REGN	Larger diversified biotechnology company useful for commercial and late-stage execution context, but not a close respiratory or bronchiectasis peer.
GILD	Large commercial biopharma benchmark with specialty-disease exposure; scale and portfolio differences limit direct valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ALNY

Similar-size biopharma benchmark with commercial and pipeline exposure, but different modalities and disease focus make it an indirect comp.

REGN

Larger diversified biotechnology company useful for commercial and late-stage execution context, but not a close respiratory or bronchiectasis peer.

GILD

Large commercial biopharma benchmark with specialty-disease exposure; scale and portfolio differences limit direct valuation comparability.